Aaron Gerds, MD

Articles

Dr Gerds on Efficacy Data Supporting the Use of Momelotinib in Myelofibrosis With Anemia

December 17th 2024

Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

October 14th 2024

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

August 6th 2024

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

Dr Gerds on Disease Progression Patterns in Low-Risk Myelofibrosis

July 10th 2024

Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis.

Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

June 14th 2024

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

May 31st 2024

Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.

Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor–Naive Myelofibrosis

January 4th 2024

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Looking Ahead in Treating Myeloproliferative Neoplasms

April 26th 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

April 26th 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Novel Therapies Under Investigation for Myelofibrosis

April 19th 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Treatment Sequencing Approaches for Myelofibrosis

April 19th 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Monitoring Strategies in Myelofibrosis

April 12th 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

JAK Inhibitors in Myelofibrosis

April 12th 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Transplant Therapy in Myelofibrosis

April 5th 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Myelofibrosis: Diagnosis and Prognostic Risk Assessment

April 5th 2023

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Myelofibrosis: Classification, Risk Factors, and Biomarkers

March 29th 2023

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Polycythemia Vera: Prognosis and Risk for Progression to Myelofibrosis

March 29th 2023

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

Systemic Treatment Options for Polycythemia Vera

March 22nd 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

Overview of MPNs

March 22nd 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

January 6th 2023

Dr Aaron Gerds provides insights and reviews updated data from the MOMENTUM study that evaluated the use of momelotinib in patients with myelofibrosis who previously received a JAK inhibitor.